PATENT CLAIM ANALYSIS

Application Number: 16033477
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["424", "143100"]

Abstract:
The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.

Claim (Index 22):
A method for treating a cancer, reducing tumor growth and/or causing tumor regression in a patient, the method comprising administering to a patient in need thereof a first antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof and a cytotoxin, wherein the antibody or antigen-binding fragment of the first ADC specifically binds EGFRvIII but does not bind the junctional peptide of SEQ ID NO:148 or the peptide of SEQ ID NO:165.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 95.0
- Lexical Diversity: 1.67925
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15170628', '14643886', '15051580', '14464297', '15289032']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7650968240197593
- 35 USC 102 Novelty (BERT): 0.6851072538613342
- Combined Prediction Score: 0.7570978670039169
- Mean Citation Score: 582.8586280000002
- Max Citation Score: 722.5108
- Similarity Product: 670.9093700727941

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test